Immunoadsorption in a dog with severe immune mediated hemolytic anemia

Area of Science:

• Veterinary Medicine
• Immunology
• Hematology

Background:

• Immune-mediated hemolytic anemia (IMHA) is a severe autoimmune disease causing red blood cell destruction.
• Standard treatments include immunosuppressants and blood transfusions, but efficacy can be limited in severe cases.
• Immunoadsorption (IA), used in human medicine for antibody removal, has not been widely explored in veterinary IMHA.

Observation:

• A five-year-old Entlebucher Mountain dog with severe IMHA refractory to immunosuppressive therapy (prednisolone, mycophenolate) and requiring multiple blood transfusions was treated with IA.
• IA was performed using COM.TEC and ADAsorb platforms with a Staphylococcus antitoxin A column.
• Complications during IA included vomiting, lid swelling, shivering, clotting, and hypotension.

Findings:

• Following IA, immediate cessation of hemolysis was observed.
• Plasma concentrations of immunoglobulin G, immunoglobulin M, and bilirubin decreased post-IA.
• Hematocrit remained stable, and the dog was discharged without further hemolysis.

Implications:

• Immunoadsorption (IA) appears to be a promising adjunctive therapy for severe, life-threatening cases of canine immune-mediated hemolytic anemia.
• Further studies are needed to determine the specific contribution of IA versus concurrent immunosuppression in resolving hemolysis.
• IA offers a potential new treatment avenue for refractory autoimmune hemolytic anemias in veterinary patients.